NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

NeOnc Technologies Holdings, Inc. (NTHI) Stock Analysis

NeOnc Technologies Holdings, Inc. (NTHI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NTHI

$2.90

+$0.13 (+4.69%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NTHI with… →

NTHI Key Statistics

As of Oct 21, 2026
Trading
Open
$2.80
Previous Close
$2.77
Day's Range
2.75–2.96
52-Week Range
2.50–12.00
Volume
106.15K
Valuation
Market Cap
$83.54M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2,088.91
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.13
Financials (FY)
Revenue (FY)
$39.99K−51.82%
Net Income (FY)
−$62.15M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
28.81M
1-Year Return
−69.38%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
198.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NTHI closed at $2.90, −69.38% over 1 year.

NeOnc Technologies Holdings, Inc. (NTHI) has a market capitalization of $83.54M.

In fiscal 2025, NTHI reported revenue of $39.99K.

NTHI Stock Return by Calendar Year

NeOnc Technologies Holdings, Inc. (NTHI) return since Mar 2025: what $10,000 became

1 year
$10,000 $3,062
−69.38%
Since Mar 2025
$10,000 $2,395
−76.05%

If you had invested $10,000 in NeOnc Technologies Holdings, Inc. (NTHI) at the close on March 26, 2025, the earliest close on record here, it would have been worth $2,395 at the close on October 21, 2026: −76.05% in total, −59.73% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−64.93%
2025 (partial year)−31.71%

As of October 21, 2026.

NTHI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$39.99K−$62.15M−155,404.4%
2024$83.00K−$11.90M−14,335.5%
2023$70.46K−$14.92M−21,176.0%
2022$20.00K−$3.05M−15,233.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$39.99K—−$58.17M−$62.15M−155,404.4%
2024$83.00K—−$7.14M−$11.90M−14,335.5%
2023$70.46K—−$8.10M−$14.92M−21,176.0%
2022$20.00K—−$2.84M−$3.05M−15,233.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

NeOnc Technologies Holdings, Inc. (NTHI) carries a market capitalisation of $83.54M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 5 employees.

Over the past 52 weeks the price has ranged from $2.50 to $12.00. NTHI last closed at $2.90 on October 21, 2026. That is +$0.13 (+4.69%) against the previous close. The latest close sits 15.95% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $39.99K. Against the prior fiscal year total of $83.00K, that is a change of −51.82%. The same year closed with a net loss of $62.15M. Trailing earnings per share are −2.13.

Across the 4 fiscal years on file, revenue moves from $20.00K in 2022 to $39.99K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 2,088.91. On price-to-sales that is 157.1 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −69.38%. The stored price history starts on March 26, 2025, and the total return since then is −76.05%. Daily returns over the trailing 1 year annualize to a volatility of 111.88%.

Growth & Income

The record shows no dividend for NTHI.

So far in 2026 the total return is −64.93%.

Peer Comparison

NeOnc Technologies Holdings, Inc. (NTHI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NeOnc Technologies Holdings, Inc. NTHI $83.54M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. NeOnc Technologies Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.

Visit website →